Cohort Study

Corneal parameters 18 Months following collagen cross-linkage treatment (CXL) for keratoconus in western Saudi Arabia: A prospective cohort study

Ashjan Bamahfouz, Serene Jouhargy, Ahmed Basheikh, Nawaf Alqahtani, Yaser Elhams, Ayat Aldosari, Faisal Khattab, Ensa Alkhoutani, Khadija Alfaqih

Department of Ophthalmology, Umm Al-Qura University, Mecca, Saudi Arabia
Department of Ophthalmology, Basafar Eye Centre, Jeddah, Saudi Arabia
Department of Ophthalmology, King Abdulaziz University, Jeddah, Saudi Arabia
Department of Ophthalmology, King Abdullah Medical City, Mecca, Saudi Arabia
Department of Ophthalmology, King Abdullah Medical City, Mecca, Saudi Arabia

ARTICLE INFO

Keywords:
Keratoconus
Corneal dystrophies
Corneal ectasia
Collagen cross-linkage

ABSTRACT

Introduction: Keratoconus is a common disease in the general population, with prevalence ranging up to 200 per 100 000 with a reported increase in Saudi Arabia. Collagen Cross-Linkage is now an established treatment in isolation and in conjunction with other modalities for managing keratoconus. Our aim is to evaluate using a cohort study the impact of the treatment over a course of 18 months.

Methods: To evaluate the impact of 18 months after collagen cross-linkage treatment and its determinants in eyes with keratoconus in Western Saudi Arabia. A one-armed prospective cohort study design on 45 patients with Stage I, II, III and IV keratoconus who were treated by Collagen Cross-Linkage modality was developed at our institute between 2018 and 2019 to establish the success rate of corneal ectasia stabilization of the disease.

Results: Demographic data and grades of keratoconus (Amsler - Krumiech classification) at presentation were correlated to changes in corneal parameters 18 months after CXL compared to that at presentation. Stage I, II, III and IV keratoconus were 13, 14, 2 and 16 eyes respectively. The study showed that the K max significantly declined (P = 0.05) while spherical equivalent refractive status changed from median −1.5D to −2.27D (P = 0.002). Meanwhile, Central corneal thickness significantly reduced (P < 0.001).

Conclusion: CXL can prove to be efficient in the treatment of Keratoconus and more studies should study ways to improve and implement this treatment plan to such patients.

1. Introduction

Keratoconus (KC) is a progressive, bilateral, asymmetrical corneal degeneration. KC is a common disease in the general population, with prevalence rate of 200 per 100 000. Twenty percent of keratoconus patients present with irregular astigmatism leading to severe visual deterioration [1]. The inciting mechanism for keratoconus remains unknown, however genetic and environmental factors have been implicated. Environmental factors include excessive eye rubbing, allergy and sun exposure which can lead to greater expression of reactive oxygen species [2]. Nonetheless, Collagen cross-linkage (CXL) is now an established treatment in isolation and in conjunction with other modalities of managing keratoconus [3,4].

Even though Keratoconus is highly prevalent in Saudi Arabia [5], CXL is now becoming an established procedure in different eye institutions in Saudi Arabia with promising outcomes [6,7]. Meanwhile, the earlier publications from central, eastern and western cities of the Kingdom were followed up for 12 months. Therefore, a study about outcome of collagen cross-linkage was sought to shed more light on the disease outcome. To the best of our knowledge, this is the no published studies to assess the outcome of collagen cross-linkage treatment from Macca city of western Saudi Arabia with a long term follow up of more than 12 months. For that, we present outcomes of this prospective study of collagen cross-linkage treatment and its determinants after 18 months in eyes with keratoconus at Macca, Saudi Arabia.

2. Materials and methods

This study was approved by the institutional review board of King Abdulla Medical City, Saudi Arabia registered at the National
Biomedical Ethics Committee, King Abdullah City for Science and Technology and was registered in the Research Registry with ID: researchregistry5660. All keratoconus patients treated with CXL between June 2017 and March 2018 were invited to participate in this study. After their informed written consent, they were included in the study. Their identity was delinked from the data prior to analysis to maintain confidentiality. An eye with central corneal thickness less than 400 μm was excluded for CXL and present study as well as patients who underwent other corneal surgical procedures in the eye to be treated by CXL were also excluded. Afterwards, the rest of patients diagnosed with Keratoconus were then included.

For a one-armed cohort, we assumed that $K_{\text{max}}$ improves in three forth of eyes treated with CXL. To achieve a 95% confidence interval and 80% power in the one-armed cohort, we need to study at least 41 eyes with keratoconus. To compensate for the loss of participants in 18 months of follow up, we increased the sample to 45. We used OpenEpi software to calculate the sample size [8].

Three cornea surgeons managed these cases with minimum 10 years of experience. The demographic data included the age and gender of the participant. In the case of bilateral keratoconus, the eye planned for the 1st CXL procedure was included in the study.

Distance vision was assessed using a projection chart to document the best-corrected distance visual acuity (BCVA) using pinhole and documented in decimal notation. Moreover, $K_{\text{max}}$ and the central corneal thickness (CCT) was measured using Pentacam tomograph (Oculus Optikgeräte GmbH, Wetzlar, Germany). The refraction was carried out using cycloplegic refraction using 0.5% tropicamide eye drops. To calculate spherical equivalent, we used formula sphere $+ (\text{cylinder}/2)$.

Corneal topography was done using OPD Scan III (NIDEK Co. Ltd., Gamagori, Japan). Based on $K_{\text{max}}$, the keratoconus was graded using the Amsler-Krumiech classification [9]. Eyes with KC were grouped into Stage I ($K \leq 48.0\, \mu m$), Stage II ($48.1\, \mu m \leq K \leq 53.0\, \mu m$), Stage III ($53.1\, \mu m \leq K \leq 55.0\, \mu m$) and Stage IV ($55.1\, \mu m \leq K$). The details of the CXL applications that was used (Dresden protocol) in the present study are described in details in the literature [10]. All patients underwent the epi-off technique. The eye was prepared in a sterile fashion and topical anesthesia was instilled in the operative eye and a lid speculum was inserted. The epithelium was removed by mechanical debridement using a number 64 blade. Riboflavin drops were instilled on the cornea every 2 min over 30 min. The eye was then exposed to ultraviolet-A light for 3 light. A bandage contact lens was placed on the cornea. Postoperatively, the patients were prescribed topical antibiotics for one week as well as a tapered schedule of a topical steroid and topical lubricants four times a day for two months or longer as needed.

The data was collected using a pretested data collection form. Data was filtered and transferred into a spreadsheet of statistical package for social studies; SPSS V 22.0 (IBM Corp., Armonk, NY, USA). Numerical data are presented as mean, median, standard deviation with inter-quartile range (IQR). Preoperative data were compared to postoperative data using the Wilcoxon Signed Ranks Test. All alpha values were 2 sided and a P value less than 0.05 was considered statistically significant. This study has been reported in accordance to the STROCSS guidelines [11].

### 3. Results

Our cohort included 45 eyes of 45 patients with keratoconus with 6 cases lost in follow up decreasing it to a total of 39 patients. The mean age was $25 \pm 5.3$ years with males mean age of 25 (55.6%), right eye (22; 48.9%) and 38 eyes had unilateral KC. Moreover, regarding the grades of KC apart from stage III, all other stages of KC were equally distributed (Fig. 1).

The corneal parameters, refractive status and visual acuity at presentation and 18 months after CXL treatment is compared in Table 1. The $K_{\text{max}}$ significantly declined (Wilcoxon $P = 0.05$). The success of stabilizing keratoconus was achieved in 29/39 = 74.4% (95% CI 60.7; 88.1). If all missing 6 cases on the follow up were stable, then the success rate would be 77.8%. But if all 6 missing cases were assumed to have deterioration of $K_{\text{max}}$, then the success rate would be 64.4%.

We associated the success to stabilize corneal curvature 18 months after CXL to the grade of keratoconus. The success of stabilizing the corneal curvature in eyes with keratoconus at 18 months after CXL was not significantly different by the grade of keratoconus at presentation (Table 2). The change in the corneal parameter in each eye at 18 months compared to before CXL was estimated and was reviewed in a cohort of cases with KC. Table 3. CCT declined in the majority of eyes. Refractive status shifted to myopia side but less than -1D. BCVA remained the same. $K_{\text{max}}$ had marginally improved.

There were 16 of 22 male keratoconus patients with stable corneal curvature. There were 13 of 20 females with stable corneal curvature. Information of three cases was missing. Stabilization of keratoconus was not associated to gender ($P = 0.6$). Meanwhile, there were 23 out of 32 unilateral KC cases with stable corneal curvature. Furthermore, there were 13 out of 17 bilateral KC cases with stable corneal curvature. Lastly, the stabilization of keratoconus was not associated with gender ($P = 0.8$).

### 4. Discussion

In this cohort, the keratoconus cases of different grades showed stabilization of corneal curvature in nearly three fourth of eyes treated with CXL before 18 months. The corneal thickness marginally but significantly decreased, faced significant myopic shift and no change in corrected visual acuity. The stabilization was similar in all grades of keratoconus. It was not different in both genders and by laterality.

The adult Saudi population in the Macc region is 573 750 in 2017 [12]. If the prevalence of 5.6% as noted by Netto et al. [5] is applied to this population, there could be as many as 32 000 persons suffering from keratoconus. These cases need early detection and prevention measures to halt progression and keratoplasty surgeries. CXL to these identified cases shows promising results in the present study to have long term stabilization of corneal curvature and thus delay in the progression of keratoconus. Sandvik et al. [13] reported a 47% decrease in corneal transplant procedures for keratoconus that they attributed directly to the introduction of CXL. Thus, the present study in the Macc region demonstrates the benefits of CXL.

The reduction of $K_{\text{max}}$ a proxy indicator of the stable cornea following CXL in the present study was significant by hardly 0.6D. This
Table 1
Changes 18 months after and before Collagen cross linkage treatment (CXL).

| Parameter | Before CXL | 18 months after CXL | Validation (Wilcoxon P) |
|-----------|------------|----------------------|------------------------|
| Kmax      | Mean       | 52.315               | 51.604                 | 0.05*                  |
|           | Median     | 50.5                 | 49.7                   |                         |
|           | Standard Deviation | ±6.6          | ±6.2                   |                         |
|           | IQR        | 47.6; 47.4; 56.7     | 57.6                   |                         |
| CCT       | Mean       | 497                  | 488.33                 | 0.001*                 |
|           | Median     | 499                  | 499                    |                         |
|           | Standard Deviation | ±26.05       | ±43.98                 |                         |
|           | IQR        | 447; 497             | 443; 487               |                         |
| BCVA      | Mean       | 0.8                  | 0.83                   | 0.9                    |
|           | Median     | 1                    | 1                      |                         |
|           | Standard Deviation | ±0.34         | ±0.28                  |                         |
|           | IQR        | 0.45; 1.0            | 0.5; 1.0               |                         |
| Spherical equivalent | Mean | −2.4853             | −3.4740                | 0.002*                 |
|           | Median     | −1.5                 | −2.2750                |                         |
|           | Standard Deviation | ±3.2         | ±6.25                  |                         |
|           | IQR        | −4.9; −6.25; −0.19   | −0.4                   |                         |

IQR = Inter Quartile Range; CCT = Central corneal thickness; BCVA = Best corrected visual acuity.

Table 2
Decline in parameter among eye with keratoconus before & 18 months after CXL.

| Kmax      | Number | 39 | Mean | −0.6 | Median | −0.2 | Standard Deviation | ±3.34 | IQR | −1.3; 0.4 |
|-----------|--------|----|------|------|--------|------|-------------------|-------|-----|-----------|
| CCT       | Number | 39 | Mean | −11.7| Median | −9.5| Standard Deviation | ±15.48| IQR | −25.8; 0.0 |
| BCVA      | Number | 39 | Mean | −0.02| Median | 0.0 | Standard Deviation | ±0.25 | IQR | −0.1; 0.1 |
| Spherical equivalent | Number | 39 | Mean | −2.02| Median | −1.1| Standard Deviation | ±7.2  | IQR | −1.7; 0.25 |

CCT = Central corneal thickness; BCVA = Best corrected visual acuity.

Table 3
Stabilization of keratoconus 18 months after collagen cross linkage by the stage of keratoconus.

| Keratoconus stage based on Kmax before CXL | Improved/stable | Progression | Validation |
|-------------------------------------------|-----------------|-------------|------------|
|                                            | Number | %     | Number | %     |          |
| Stage I (N = 11)                          | 9      | 81.8  | 2      | 18.2  | §2 = 2.2 |
| Stage II (N = 12)                         | 9      | 81.8  | 2      | 18.2  | Df = 4   |
| Stage III (N = 2)                         | 2      | 100   | 0      | 0.0   | P = 0.14 |
| Stage IV (N = 15)                         | 9      | 60    | 6      | 40    |           |
| Total (Missing = 6)                       | 29     | 74.4  | 10     | 25.6  |           |

5. Conclusions

Collagen cross-linkage in a country where the magnitude of keratoconus is on rising and availability of donor cornea is limited, CXL will be the choice of intervention at many institutions. These institutions with small samples may not be able to interpret the outcomes so as to propose a revision of protocol to improve outcome and therefore meta-analysis is recommended. Steep cornea seems to be a good indicator to judge the success of flattening the cornea by subjecting a KC eye with CXL. However, CXL should be monitored for a long time to ensure further things may not result in sign threatening complications. Cornea surgeons if trained in undertaking concurrent refractive surgery in the KC eye, both progression can be stopped, and refractive status can also be improved.
Ethical approval

The IRB of King Abdulaziz City for Science and Technology.

Author contribution

All authors were part of designing, data collection, writing, analysis, proofreading and referencing of this study.

Registration of research studies

1. Name of the registry: Research Registry.
2. Unique Identifying number or registration ID: 5660.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): https://www.researchregistry.com/browse-the-registry#home/registrationdetails/5ed3a786cd312c001519d8d6/.

Guarantor

Ashjan Bamahfouz.
Ashjanmd@gmail.com.

Consent

Ethical approval and consent taken.

Funding

None.

Provenance and peer review

Not commissioned, externally peer reviewed.

Declaration of competing interest

The authors declare no conflict of interest.

Acknowledgments

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2020.09.010.

References

[1] K.K. Abu-Amero, A.M. Al-Muammar, A.A. Kondkar, Genetics of keratoconus: where do we stand? J. Ophthalmol. 2014 (2014) 641708.
[2] A. Gordon-Shaag, M. Millodot, E. Shneor, Y. Liu, The genetic and environmental factors for keratoconus, BioMed Res. Int. 2015 (2015) 795738.
[3] F. Raiskup, A. Theuring, L.E. Pillunat, E. Spoerl, Corneal collagen crosslinking with riboflavin and ultraviolet-A light in progressive keratoconus: ten-year results, J. Cataract Refract. Surg. 41 (1) (2015), 41-6.
[4] A. Stuart, CXL for corneal ectasia: reshaping the future of treatment: American academy of ophthalmology, Available from: https://www.aao.org/eyenet/article/corneal-ectasia-reshaping-future-of-treatment?april-2014, 2019.
[5] E.A. Torres Netto, W.M. Al-Otaibi, N.L. Hafezi, S. Kling, H.M. Al-Farhan, J. B. Randleman, et al., Prevalence of keratoconus in paediatric patients in Riyadh, Saudi Arabia, Br. J. Ophthalmol. 102 (10) (2018) 1436–1441.
[6] A. Khattak, F.R. Nakhli, H.R. Cheema, Corneal collagen crosslinking for progressive keratoconus in Saudi Arabia: one-year controlled clinical trial analysis, Saudi J. Ophthalmol. 29 (4) (2015) 249–254.
[7] M.F. Jankov Ii, V. Jovanovic, S. Delevic, E. Coskunseven, Corneal collagen cross-linking for treating keratoconus, Cochrane Database Syst. Rev. (3) (2015) Cd010621.
[8] K.M. Sullivan, A. Dean, M.M. Soe, OpenEpi: a web-based epidemiologic and statistical calculator for public health, Publ. Health Rep. 124 (3) (2009) 471–474.
[9] K. Kamiya, R. Ishii, K. Shimizu, A. Igarashi, Evaluation of corneal elevation, pachymetry and keratometry in keratoconic eyes with respect to the stage of Amstler-Krumeich classification, Br. J. Ophthalmol. 98 (4) (2014) 459–463.
[10] G. Wolfensak, E. Spoerl, T. Seiler, Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus, Am. J. Ophthalmol. 135 (5) (2003) 620–627.
[11] R. Agha, A. Abdali-Razak, E. Croxley, N. Dowlut, C. Joshi, G. Mathew, STROCSS 2019 Guideline: strengthening the reporting of cohort studies in surgery, Int. J. Surg. 72 (2019) 156–165.
[12] Statistics GAf, Population in Saudi Arabia by gender, age, nationality (Saudi/non-Saudi), Available from: stats.gov.sa/en/5305, 2016.
[13] E. Sykakis, R. Karim, J.R. Evans, C. Bunce, K.N. Amissah-Arthur, S. Patwary, et al., Evaluation of corneal collagen crosslinking for progressive keratoconus: a prospective randomized controlled trial, Cornea 34 (Suppl 10) (2015) S53-S56.
[14] A.M. Sherif, M.A. Ammar, Y.S. Mostafa, S.A. Gamal Eldin, A.A. Osman, One-Year results of simultaneous topography-guided photorefractive keratectomy and corneal collagen crosslinking in keratoconus utilizing a modern ablation software, J Ophthalmol 2015 (2015) 321953.
[15] R. Izbaren, Axial length increasing with age, Ophthalmology 118 (4) (2011) 249–254.
[16] C. Mazzotta, C. Traversi, S. Baiocchi, S. Bagaglia, O. Caporossi, A. Villano, et al., Evaluation of corneal collagen cross-linking for keratoconus patients comparing anterior and posterior keratometry results, J. Cataract Refract. Surg. 24 (7) (1995) 785–786.
[17] V. Bhardwaj, G.P. Rajeshbhai, Axial length, anterior chamber depth-a study in axial length increasing with age, Ophthalmology 118 (4) (2011) 249–254.
[18] M.R. Jankov Ii, V. Jovanovic, S. Delevic, E. Coskunseven, Corneal collagen cross-linking reduce the need for keratoplasties in patients with keratoconus? Cornea 34 (9) (2015) 991–995.
[19] V. Bhardwaj, G.P. Rajeshbhai, Axial length, anterior chamber depth-a study in axial length increasing with age, Ophthalmology 118 (4) (2011) 249–254.
[20] K.M. Sullivan, A. Dean, M.M. Soe, OpenEpi: a web-based epidemiologic and statistical calculator for public health, Publ. Health Rep. 124 (3) (2009) 471–474.
[21] V. Bhardwaj, G.P. Rajeshbhai, Axial length, anterior chamber depth-a study in axial length increasing with age, Ophthalmology 118 (4) (2011) 249–254.
[22] C. Wittig-Silva, M. Whiting, E. Lamoureux, R.G. Lindsay, L.J. Sullivan, G. R. Shetty, N.K. Pahuja, R.M. Nuijts, A. Ajani, C. Jayadev, C. Sharma, et al., Current guidelines for the management of keratoconus: a review of existing evidence, Surv. Ophthalmol. 52 (6) (2007) 441–456.
[23] G. Wollensak, E. Spoerl, T. Seiler, Riboflavin/ultraviolet-a-induced collagen crosslinking for progressive keratoconus: preliminary results of simultaneous topography-guided photorefractive keratectomy and corneal collagen crosslinking in keratoconus utilizing a modern ablation software, J Ophthalmol 2015 (2015) 321953.
[24] R. Izbaren, Axial length increasing with age, Ophthalmology 118 (4) (2011) 785–786.
[25] V. Bhardwaj, G.P. Rajeshbhai, Axial length, anterior chamber depth-a study in axial length increasing with age, Ophthalmology 118 (4) (2011) 249–254.
[26] C. Wittig-Silva, M. Whiting, E. Lamoureux, R.G. Lindsay, L.J. Sullivan, G. R. Shetty, N.K. Pahuja, R.M. Nuijts, A. Ajani, C. Jayadev, C. Sharma, et al., Current guidelines for the management of keratoconus: a review of existing evidence, Surv. Ophthalmol. 52 (6) (2007) 441–456.
[27] E. Sykakis, R. Karim, J.R. Evans, C. Bunce, K.N. Amissah-Arthur, S. Patwary, et al., Evaluation of corneal collagen crosslinking for progressive keratoconus: ten-year results, Cornea 37 (5) (2018) 560–569.